Standard

Toward gene therapy of hypertension : Experimental study on hypertensive ISIAH rats. / Repkova, M. N.; Levina, A. S.; Seryapina, A. A. et al.

In: Biochemistry (Moscow), Vol. 82, No. 4, 01.04.2017, p. 454-457.

Research output: Contribution to journal › Article › peer-review

Harvard

Repkova, MN, Levina, AS, Seryapina, AA, Shikina, NV, Bessudnova, EV, Zarytova, VF & Markel, AL 2017, 'Toward gene therapy of hypertension: Experimental study on hypertensive ISIAH rats', Biochemistry (Moscow), vol. 82, no. 4, pp. 454-457. https://doi.org/10.1134/S000629791704006X

APA

Repkova, M. N., Levina, A. S., Seryapina, A. A., Shikina, N. V., Bessudnova, E. V., Zarytova, V. F., & Markel, A. L. (2017). Toward gene therapy of hypertension: Experimental study on hypertensive ISIAH rats. Biochemistry (Moscow), 82(4), 454-457. https://doi.org/10.1134/S000629791704006X

Vancouver

Repkova MN, Levina AS, Seryapina AA, Shikina NV, Bessudnova EV, Zarytova VF et al. Toward gene therapy of hypertension: Experimental study on hypertensive ISIAH rats. Biochemistry (Moscow). 2017 Apr 1;82(4):454-457. doi: 10.1134/S000629791704006X

Author

Repkova, M. N. ; Levina, A. S. ; Seryapina, A. A. et al. / Toward gene therapy of hypertension : Experimental study on hypertensive ISIAH rats. In: Biochemistry (Moscow). 2017 ; Vol. 82, No. 4. pp. 454-457.

BibTeX

@article{27f3b419693a418fa58e4b83a58ef240,
title = "Toward gene therapy of hypertension: Experimental study on hypertensive ISIAH rats",
abstract = "TiO2-based nanocomposites were prepared to deliver oligonucleotides into cells. The nanocomposites were designed by the immobilization of polylysine-containing oligonucleotides on TiO2-nanoparticles (TiO2·PL-DNA). We showed for the first time the possibility of using the proposed nanocomposites for treatment of hypertensive disease by introducing them into hypertensive ISIAH rats developed as a model of stress-sensitive arterial hypertension. The mRNA of the gene encoding angiotensin I-converting enzyme (ACE1) involved in the synthesis of angiotensin II was chosen as a target. Administration (intraperitoneal injection and inhalation) of the nanocomposite showed a significant (by 20-30 mm Hg) decrease in systolic blood pressure when the nanocomposite contained the ACE1 gene-targeted oligonucleotide. When using the oligonucleotide with a random sequence, no effect was observed. Further development and improvement of the inhalation nanocomposite drug delivery to systemic hypertensive disease treatment promises new possibilities for clinical practice.",
keywords = "antisense oligonucleotides, hypertension, ISIAH rats, nanocomposites, NANOPARTICLES, NANOCOMPOSITES, INFLUENZA-A VIRUS, ANTISENSE, DISEASE, STRESS, BLOOD-PRESSURE, DELIVERY",
author = "Repkova, {M. N.} and Levina, {A. S.} and Seryapina, {A. A.} and Shikina, {N. V.} and Bessudnova, {E. V.} and Zarytova, {V. F.} and Markel, {A. L.}",
year = "2017",
month = apr,
day = "1",
doi = "10.1134/S000629791704006X",
language = "English",
volume = "82",
pages = "454--457",
journal = "Biochemistry (Moscow)",
issn = "0006-2979",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "4",

}

RIS

TY - JOUR

T1 - Toward gene therapy of hypertension

T2 - Experimental study on hypertensive ISIAH rats

AU - Repkova, M. N.

AU - Levina, A. S.

AU - Seryapina, A. A.

AU - Shikina, N. V.

AU - Bessudnova, E. V.

AU - Zarytova, V. F.

AU - Markel, A. L.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - TiO2-based nanocomposites were prepared to deliver oligonucleotides into cells. The nanocomposites were designed by the immobilization of polylysine-containing oligonucleotides on TiO2-nanoparticles (TiO2·PL-DNA). We showed for the first time the possibility of using the proposed nanocomposites for treatment of hypertensive disease by introducing them into hypertensive ISIAH rats developed as a model of stress-sensitive arterial hypertension. The mRNA of the gene encoding angiotensin I-converting enzyme (ACE1) involved in the synthesis of angiotensin II was chosen as a target. Administration (intraperitoneal injection and inhalation) of the nanocomposite showed a significant (by 20-30 mm Hg) decrease in systolic blood pressure when the nanocomposite contained the ACE1 gene-targeted oligonucleotide. When using the oligonucleotide with a random sequence, no effect was observed. Further development and improvement of the inhalation nanocomposite drug delivery to systemic hypertensive disease treatment promises new possibilities for clinical practice.

AB - TiO2-based nanocomposites were prepared to deliver oligonucleotides into cells. The nanocomposites were designed by the immobilization of polylysine-containing oligonucleotides on TiO2-nanoparticles (TiO2·PL-DNA). We showed for the first time the possibility of using the proposed nanocomposites for treatment of hypertensive disease by introducing them into hypertensive ISIAH rats developed as a model of stress-sensitive arterial hypertension. The mRNA of the gene encoding angiotensin I-converting enzyme (ACE1) involved in the synthesis of angiotensin II was chosen as a target. Administration (intraperitoneal injection and inhalation) of the nanocomposite showed a significant (by 20-30 mm Hg) decrease in systolic blood pressure when the nanocomposite contained the ACE1 gene-targeted oligonucleotide. When using the oligonucleotide with a random sequence, no effect was observed. Further development and improvement of the inhalation nanocomposite drug delivery to systemic hypertensive disease treatment promises new possibilities for clinical practice.

KW - antisense oligonucleotides

KW - hypertension

KW - ISIAH rats

KW - nanocomposites

KW - NANOPARTICLES

KW - NANOCOMPOSITES

KW - INFLUENZA-A VIRUS

KW - ANTISENSE

KW - DISEASE

KW - STRESS

KW - BLOOD-PRESSURE

KW - DELIVERY

UR - http://www.scopus.com/inward/record.url?scp=85017514264&partnerID=8YFLogxK

U2 - 10.1134/S000629791704006X

DO - 10.1134/S000629791704006X

M3 - Article

C2 - 28371602

AN - SCOPUS:85017514264

VL - 82

SP - 454

EP - 457

JO - Biochemistry (Moscow)

JF - Biochemistry (Moscow)

SN - 0006-2979

IS - 4

ER -

ID: 8673295